PBM Capital — Full Portfolio
7 tracked investments · listed companies and verified rows first
BiotechMorrisville, US
Damian deGoa(Executive Officer, Director)Michael Kaseta(Executive Officer)
BoardStephen Bloch(Director)inJoanna Horobin(Director)Raman Singh(Director)
Board seatPaul B. Manning· per SEC Form D · $21.7M raise · filed Apr 2021
Co-investorsCanaan PartnersNew Enterprise Associates (NEA)
Taysha Gene Therapies develops and commercializes gene therapies for monogenic diseases of the central nervous system, serving patients with rare and larger CNS conditions.
BiotechDeep TechDigital HealthHealthtechMedical DevicesTexas, US
R.A. Session II(Executive Officer, Director)Sean P. Nolan(Chief Executive Officer and Board Chairman)in
BoardSean Nolan(Director)
Board seatPaul B. Manning· per SEC Form D · $30M raise · filed Nov 2022
Co-investorsGV (Google Ventures)
Publicly listed pharmaceutical company
BiotechWest Chester, US
Noah Rosenberg(Executive Officer)John Kirby(Executive Officer)Matthew Davidson(Executive Officer, Director)
BoardDavid Zawitz(Executive Officer)
Board seatPaul B. ManningJayson Rieger· per SEC Form D
HealthtechBoulder, US
Jason Myers(Executive Officer, Director)Christian LaPointe(Executive Officer)
BoardKyle Lefkoff(Director)inPaul Manning(Director)
Board seatPaul B. Manning· per SEC Form D · $1.6M raise · filed Apr 2020
Co-investorsCrawley VenturesBoulder VenturesLongwood Fund
BiotechCharlottesville, US
Raymond Chavez(Executive Officer, Director)Stephen Collins(Executive Officer, Director)Linda Watkins(Director)
BoardPeter Heinecke(Director)John Forsayeth(Director)
Board seatPaul B. ManningJayson Rieger· per SEC Form D · $30M raise · filed Jun 2021
Co-investorsForesite CapitalRA Capital
Publicly listed pharmaceutical company
BiotechCharlottesville, US
Eugene R. Scavola(Executive Officer, Promoter)Damian deGoa(Executive Officer, Promoter)
BoardRussell T. Schundler(Executive Officer, Promoter)James C. Reebals(Executive Officer, Promoter)Hossein Ekrami(Director)John A. Stalfort(Executive Officer, Director, Promoter)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.